Inmune Bio, Inc. 10-Q — AI Bull & Bear Analysis

The Q1 2026 filing presents a classic biotech trade-off between imminent regulatory catalysts and severe balance sheet fragility. On one hand, the completion of the MissionEB study and the securing of exclusive data rights from Great Ormond Street Hospital provide a clear path toward commercialization of CORDStrom. The reduction in burn rate suggests a more focused management approach, and the utilization of international tax credits provides a temporary lifeline. However, the structural risks are undeniable. The company's reliance on a single orphan indication and its admission of substantial doubt regarding its ability to continue as a going concern create a high-risk environment. Investors must weigh the potential for a binary regulatory win against the high probability of further equity dilution and the looming pressure of milestone payments. The overall impact of the filing is a heightened urgency for a capital infusion or a strategic partnership to bridge the gap to 2026 approvals.